“For a breakthrough medication to be effective, it needs to be affordable, yet drug makers fail time and time again to abide by this fundamental principle. The Campaign commends the Senate Special Committee on Aging for challenging the pharmaceutical industry on the irresponsible pricing strategies that deliberately deny patients and consumers access to affordable treatments." Read More
“This latest analysis from the Kaiser Family Foundation paints a troubling picture for the future of the Medicare Part D program and beneficiaries who rely on access to affordable treatments." Read More
“As we all focus on how to ensure patients get the medications they need at an affordable price, we commend Senators Wyden and Grassley for undertaking this important investigation and for raising awareness around this rapidly growing issue for both sides of the aisle." Read More
"With presidential candidates on both sides of the aisle actively talking about unsustainable prescription drug pricing, the issue is clearly bigger than politics — it’s about protecting American families and ensuring they can access the critical treatments they need at prices they can afford." Read More
Report: Prescription Drug Spending Tops Year-Over-Year Price Growth for Major… Read More
Exorbitant price tags associated with breakthrough treatments illustrate the broader challenges ahead for the U.S. health care system if excessive drug pricing is not addressed head on. Read More
As the 2016 presidential race heats up, prominent candidates are beginning to unveil comprehensive plans to address soaring prescription drug costs and the harmful impact their price tags have on Americans. Read More
"This latest health care price growth report indicates that spending on pricey prescription medications shows no sign of slowing down. When compared to other health care services, it is clear that high cost treatments continue to top the charts as a serious threat to the sustainability of our health care system and beyond." Read More
“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.” Read More
“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.” Read More
PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices Read More
Exorbitant price tags for specialty medications are taking a serious financial toll on state budgets. A new analysis released yesterday from the California Association of Health Plans (CAHP) shows that treating only 10 percent of 175,000 patients in state-funded health care programs with just three hepatitis C medications would cost California roughly $1-2 billion. Read More